论文部分内容阅读
[目的]探讨紫杉醇脂质体联合顺铂、替加氟作为二线方案治疗转移性食管癌的疗效和安全性。[方法]26例转移性食管癌患者使用紫杉醇脂质体80mg/m2静脉滴注3h,d1,8;顺铂20mg/m2,静脉滴注,d1～3;甲酰四氢叶酸200mg/m2,静脉滴注2h,d1～3;替加氟600mg/m2,静脉滴注,d1～3;28d为1个周期。[结果]26例患者共完成99周期化疗,平均3.81个周期。8周后复查CT结果显示:完全缓解(CR)2例(7.7%),部分缓解(PR)9例(34.6%),稳定(SD)8例(30.8%),进展(PD)7例(26.9%),有效率(RR)为42.3%(11/26),疾病控制率73.1%(19/26)。中位疾病进展时间(TTP)为4.8个月(95%可信区间,2.8～8.2月),中位生存期(MST)为8.4个月(95%可信区间,4.1～13.2月),1年生存率为11.5%(3/26)。毒性反应较小,主要是中性粒细胞减少。[结论]紫杉醇脂质体联合顺铂、替加氟作为二线方案治疗转移性食管癌具有较好的疗效和安全性。
[Objective] To investigate the efficacy and safety of paclitaxel liposome combined with cisplatin and tegafur in the treatment of metastatic esophageal cancer as a second-line regimen. [Method] Twenty-six patients with metastatic esophageal cancer were treated with paclitaxel liposome 80mg / m2 intravenously for 3h, d1,8; cisplatin 20mg / m2, intravenous drip, d1-3; leucovorin 200mg / m2, Intravenous infusion 2h, d1 ~ 3; tegafur 600mg / m2, intravenous infusion, d1 ~ 3; 28d for a cycle. [Results] Twenty-six patients completed 99 cycles of chemotherapy, with an average of 3.81 cycles. After 8 weeks of review, the CT findings showed that CR was 2 cases (7.7%), partial remission (PR) 9 cases (34.6%), stable (SD) 8 cases 26.9%), the effective rate (RR) was 42.3% (11/26) and the disease control rate was 73.1% (19/26). The median time to progression (TTP) was 4.8 months (95% confidence interval, 2.8-8.2 months) and the median survival time (MST) was 8.4 months (95% confidence interval, 4.1-1.3.2 months) The annual survival rate was 11.5% (3/26). Toxicity is less, mainly neutropenia. [Conclusion] paclitaxel liposome combined with cisplatin and tegafur as the second-line treatment of metastatic esophageal cancer has good efficacy and safety.